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Abstract 
Background: Delay in Tuberculosis (TB) diagnosis affects foreign-born and nationals in different ways, especially in 
low-incidence countries. This study characterises total delay and its components amongst foreign-born individuals in 
Portugal. Additionally, we identify risk factors for each type of delay and compare their effects between foreign-born 
and nationals.
Methods: We analysed data from the Portuguese TB surveillance system and included individuals with pulmonary TB 
(PTB), notified between 2008 and 2017. We described patient, healthcare, and total delays. Cox regression was used to 
identify factors associated with each type of delay. All analyses were stratified according to the origin country: nation-
als (those born in Portugal) and foreign-born.
Results: Compared with nationals, foreign-born persons presented statistically significant and longer median total 
and patient delays (Total: 67 vs. 63; Patient: 44 vs. 36 days), and lower healthcare services delays (7 vs. 9 days). Risk 
factors for delayed diagnosis differed between foreign-born and nationals. Being unemployed, having drug addiction, 
and having comorbidities were identified as risk factors for delayed diagnosis in national individuals but not in for-
eigners. Alcohol addiction was the only factor identified for healthcare delay for both populations: foreign-born (Haz-
ard Ratio 1.34 [95% confidence interval 1.17;1.53]); nationals (Hazard Ratio 1.20 [95% confidence interval 1.13;1.27]).
Conclusions: Foreign-born individuals with PTB take longer to seek health care. While no specific risk factors were 
identified, more in-depth studies are required to identify barriers and support public health intervention to address 
PTB diagnosis delay in foreign-born individuals.
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Background
Tuberculosis (TB) is a curable disease but persists 
amongst the top 10 causes of death worldwide and was 
the number one infectious killer worldwide in 2018. 
TB thus remains a major public health issue in the 
twenty-first century [1]. TB infection can affect differ-
ent organs, but it typically affects the lungs (pulmonary 
TB), becoming contagious and spreading via person-to-
person transmission [2].
Appropriate and timely diagnosis is a cornerstone to 
TB control; delays in detecting TB cases are related to 
increased transmission, severity, and mortality rates [3–
6]. These can be defined as the time between symptoms 
onset and the diagnosis/beginning of treatment (total 
delay) and be divided into patient delay (time between 
symptoms onset and the first contact with health ser-
vices) and healthcare services delay (time between the 
first contact with health services and diagnosis/beginning 
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of treatment) [3, 4]. Ideally, the total delay should take no 
longer than 3–4  weeks [4, 7]. However, in Portugal the 
median delay is 80 days [8].
TB affects some areas and population groups dispro-
portionally, with immigrants in urban areas presenting 
a higher incidence than nationals [5, 6, 9–13]. Moreover, 
the overall decrease of TB cases in Europe in recent years 
[2, 8] has not been reflected in immigrants [2, 12–14]. 
Portugal follows a similar trend, with notifications of 
TB cases amongst foreign-born individuals increasing, 
reaching 20.2% from overall TB cases in 2018 [8]. (15.9% 
in 2014 [15]; 18.4% in 2016 [16]; 19.2% in 2017 [8]) [9, 12, 
17–20]. In recent years the immigrant population in Por-
tugal has also been growing annually (6.0% in 2017 [21]; 
13.9% in 2018 [20]), coming mostly from other European 
and Portuguese speaking countries [20]. Additionally, 
foreign-born individuals mainly enter Portugal with the 
purpose of settling, with refugees and asylum seekers 
accounting for very few [20]. Screening upon entrance is 
not undertaken [22].
The immigrant status is a well-known risk factor not 
only for TB disease but also for the diagnosis delay, with 
immigrants presenting significantly longer patient delays, 
which could be considered a proxy for access to health-
care services [3, 5, 7, 11–13, 18, 23–25]. Studies show 
that immigrants seek medical care at an advanced or 
intermediate TB stage [23, 24, 26–28]. Delayed seeking of 
medical care amongst immigrants is often attributed to 
an interplay of several factors, such as living and working 
conditions, legal status, poor access to services, discrimi-
nation [24], poor knowledge regarding TB, availability of 
appropriate awareness materials, communication cam-
paigns in different languages, literacy levels, and different 
sociocultural beliefs (i.e., preferring traditional healers) 
[24, 29]. However, there are limited studies addressing 
the risk factors for diagnosis delays in this specific popu-
lation and to the best of our knowledge, none has been 
conducted in Portugal. With a rising number of cases 
amongst foreign-born individuals and persistent delays in 
the diagnosis, an analysis of the factors associated with 
delays is required to design and support public health 
intervention.
Methods
This study characterises total delay and its components 
amongst foreign-born individuals in Portugal. We also 
identify risk factors for each delay type and compare the 
effects of those factors between foreign-born and nation-
als. In this study we used the individuals born outside 
Portugal (foreign-born) as a proxy for immigrant status.
We used data from the national surveillance system 
for TB (SVIG-TB [30]) between 2008 and 2017, and 
analysed all PTB cases notified in Portugal identified 
through passive case finding (i.e., presenting symp-
toms). Only PTB cases were included since it presents 
the most common and the only contagious form of the 
disease. Finally, only individuals with symptoms were 
included in the analysis in order to ascertain the time 
between the onset of symptoms and diagnosis [3, 4].
The outcomes under analysis were patient delay, 
healthcare services delay, and total delay, all meas-
ured in days. Diagnosis delay (total delay) was defined 
as the time between the date of symptoms onset and 
the diagnosis date. Patient delay was defined as the 
time between the date of symptoms onset and the first 
appointment, and healthcare services delay was defined 
as the time between the first medical appointment and 
the diagnosis date. The variables included in the analy-
ses were selected according to those identified in the lit-
erature [5, 14, 31–33], and included sex (male/female); 
age at diagnosis (in years); unemployment (yes/no); 
prison inmate (yes/no); homelessness (yes/no); com-
munity residence (yes/no); alcohol addiction (subjec-
tive information based on CAGE score [34]) (yes/no); 
drug addiction (excluding occasional use and requiring 
withdrawal symptoms) (yes/no); HIV positivity (yes/
no); comorbidities (non-respiratory/respiratory) (yes/
no). Non-respiratory comorbidities included kidney 
failure on dialysis, cancer, diabetes, liver disease, and 
respiratory comorbidities included chronic obstructive 
pulmonary disease, silicosis, interstitial pulmonary/
lung disease.
As we intended to compare delays amongst foreign-
born and nationals, all analyses were stratified based 
on the country of origin: those born outside of Portu-
gal were considered as foreign-born, while individuals 
born in Portugal were deemed nationals.
We performed a descriptive analysis to characterise 
PTB cases in foreign-born individuals and nationals. 
The median test for independent samples was used to 
compare the medians of delays in both groups. A chi-
square independence test was performed to identify the 
association between the origin country and the inde-
pendent variables. A Cox regression model was used 
to identify factors associated with the delays in for-
eign-born individuals and nationals. The initial model 
included sex and age, and the remaining variables were 
selected using backward selection. Only complete cases 
were included. Significance level was set at 5%. The 
model goodness-of-fit was assessed using concord-
ance [35]. All statistical analyses were performed using 
SPSS (version 26). As data used in these analyses are 
from an official national surveillance system and were 
previously anonymized, ethics committee approval and 
informed consent were not required.
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Results
From 2008 to 2017, 15,359 cases of PTB identified 
through passive finding were notified to SVIG-TB. 
Data were validated, and 460 cases were removed 
due to inconsistencies. The final sample size included 
14,899 cases, 15.5% of which were born outside Portu-
gal (Table 1). Foreign-born PTB cases were mainly male 
(66.7%) and aged 25–54 years old (70.7%). Foreign-born 
individuals were more frequently HIV-positive (9.4% vs. 
18.7%), homeless people (1.5% vs. 2.9%) and people liv-
ing in community residencies (3.1% vs. 4.1%). Foreign-
born individuals had lower frequency of comorbidities 
(non-respiratory—16.0% vs. 12.5%; respiratory—6.7% vs. 
1.6%), lower frequency of alcohol (15.2% vs. 13.6%) and 
drug addiction (11.1% vs. 7.4%), and lower frequency of 
imprisonment (1.9% vs. 1.7%). Statistically significant dif-
ferences (p < 0.005) were identified for all variables except 
unemployment, alcohol addiction, and incarceration.
Median patient and total delay were higher in foreign-
born individuals (44 vs. 36 days; 68 vs. 64 days, respec-
tively, both p < 0.001), while the median healthcare 
services delay was lower for this population (7 vs. 9 days, 
p = 0.005), compared with nationals, all of them statisti-
cally different.
Table  2 shows the results for the multivariable Cox 
regression model, adjusted for sex and age and the vari-
ables identified through backward selection. The out-
come corresponds to PTB diagnosis, hence an HR above 
1 indicates shorter delays as it represents a higher risk 
of having the event. Among nationals, being addicted to 
alcohol was associated with longer patient delay and hav-
ing HIV co-infection was associated with shorter patient 
delay. For the same population, living in a community 
residence and being addicted to alcohol were associ-
ated with shorter healthcare services delay, but having 
comorbidities was associated with longer healthcare ser-
vices delay. Being homeless and HIV co-infected were 
associated with shorter total delay, while being addicted 
to drugs was associated with longer total delay. Among 
foreign-born and for patient and total delays, no factors 
apart from sex or age were identified as statistically sig-
nificant. Alcohol addiction was the only factor identified 
to be associated with shorter healthcare services delay.
Discussion
This study characterises the PTB delay amongst for-
eign-born persons and nationals, considering sociode-
mographic and clinical information, and compares the 
results between these two groups. Our analysis shows 
that both the median of total delay and patient delay 
are higher for foreign-born individuals than amongst 
nationals (67 vs. 63  days and 44 vs. 36  days, respec-
tively), while the median healthcare services delay is 
lower (7 vs. 9 days). These results are in line with other 
European countries and international literature [3–5, 18, 
36]. While there is no period of time between symptoms 
onset and diagnosis has been established that is deemed 
to be acceptable, from a PTB control point of view, such 
a time-lapse should be no more than 4  weeks (about 
28 days) [4, 7, 36]. Our study reveals a delay of more than 
twice that duration, especially among foreign-born. We 
view this finding as a call for action.
Considering patient delay as a proxy for healthcare 
services access and the greater patient delay for foreign-
born, we speculate that foreign-born persons might face 
barriers while trying to access healthcare services, pos-
sibly contributing thereby to advanced PTB stages upon 
consultation [3, 18, 23, 31, 37]. A systematic review of 
qualitative studies concerning TB in immigrants identi-
fied numerous reasons contributing to the healthcare 
services delay, including misconceptions about TB, lack 
of familiarity with the local language, lack of knowl-
edge of free healthcare, inability to take off from work 
to attend a clinic appointment, and cultural differences 
with “Western” medical services [29]. This may suggest 
that these types of individual issues, such as knowledge of 
their health rights, cultural beliefs, and/or TB knowledge 
should be addressed to help identify their influence in the 
seeking of healthcare services by foreign-born persons 
diagnosed with TB. In addition, foreign-born persons 
may have certain beliefs and concepts about disease and 
health based on their ethnic and cultural background, 
influencing how they understand signs and symptoms 
[10, 23]. The role of community health workers could be 
of extreme importance to bridge the gap between foreign 
communities and healthcare services, addressing some 
barriers previously mentioned such as clarifying health 
rights and dispelling misconceptions regarding TB dis-
ease. Additionally, as the risk factors for nationals do not 
appear to be the same as those for foreign-born individu-
als, tailored studies including a qualitative component are 
needed to understand what is causing the delays amongst 
foreign-born individuals. Healthcare services delay 
(between first appointment and diagnosis/beginning of 
treatment), however, is lower in foreign-born individu-
als, which might be explained through the greater suspi-
cion for TB infection in this population, which is known 
by health professionals [5, 38]. These results corroborate 
previous studies from high-income countries, where the 
patient delay is usually longer than healthcare services 
delay [4, 39].
As also reported in other studies, foreign-born indi-
viduals were younger, had a higher percentage of HIV 
co-infection, and less alcohol and drug addiction [10, 
12, 37]. The age difference between foreign-born and 
nationals diagnosed with pulmonary TB may be due to 
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
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Table 1 Sociodemographic and clinical characteristics of nationals and foreign-born with pulmonary tuberculosis notified in SVIG-TB 
(2008–2017)
a Comparison between origin country and the independent variable through the chi-square independence test
b Includes kidney failure on dialysis, cancer, diabetes, liver disease
c Includes chronic obstructive pulmonary disease, silicosis, interstitial pulmonary/lung disease
d Human immunodeficiency virus
Variables Nationals (N,%) Foreign-born (N,%) p-valuea
N = 12,596 (84.5%) N = 2303 (15.5%)
Sex  < 0.001
Male 8934 (70.9%) 1537 (66.7%)
Female 3662 (29.1%) 766 (33.3%)
Age at diagnosis  < 0.001
0–4 59 (0.5%) 9 (0.4%)
5–14 72 (0.6%) 26 (1.1%)
15–24 1057 (8.4%) 308 (13.4%)
25–34 1844 (14.7%) 518 (22.6%)
35–44 2683 (21.3%) 646 (28.1%)
45–54 2572 (20.4%) 459 (20.0%)
55–64 1724 (13.7%) 212 (9.2%)
 ≥ 65 2573 (20.4%) 119 (5.2%)
Unemployed > 24 months 0.63
No 10,609 (84.2%) 1949 (84.6%)
Yes 1987 (15.8%) 354 (15.4%)
Alcohol addiction 0.05
No 10,031 (79.6%) 1868 (81.1%)
Yes 1910 (15.2%) 313 (13.6%)
Unknown 655 (5.20%) 122 (5.3%)
Drug addiction  < 0.001
No 10,668 (84.7%) 2016 (87.5%)
Yes 1393 (11.1%) 170 (7.4%)
Unknown 535 (4.3%) 117 (5.1%)
Imprisoned 0.61
No 12,005 (95.3%) 2186 (94.9%)
Yes 240 (1.9%) 40 (1.7%)
Unknown 351 (2.8%) 77 (3.3%)
Homelessness  < 0.001
No 12,041 (95.6%) 2159 (93.7%)
Yes 189 (1.5%) 67 (2.9%)
Unknown 366 (2.9%) 77 (3.3%)
Community residence 0.01
No 11,806 (93.7%) 2113 (91.7%)
Yes 396 (3.1%) 95 (4.1%)
Unknown 394 (3.1%) 95 (4.1%)
Comorbidities  < 0.001
No 9606 (77.3%) 1936 (85.9%)
Non-respiratoryb 1984 (16.0%) 281 (12.5%)
Respiratoryc 835 (6.7%) 36 (1.6%)
HIVd serology  < 0.001
No 10,180 (80.8%) 1668 (72.4%)
Yes 1179 (9.4%) 431 (18.7%)
Unknown 1237 (9.8%) 204 (8.9%)
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the difference in age profile between foreign-born and 
nationals or might be related to the natural history of 
TB in the origin country [12, 37]. Studies related to TB 
amongst immigrants in Europe have showed that this 
population is disproportionally affected by HIV-TB co-
infection and that the risk of substance abuse is higher 
in nationals [10, 12, 37]. This can contribute to longer 
patient delays for foreign-born individuals. These indi-
viduals also had fewer comorbidities, which is consistent 
with the literature reporting that foreign-born persons 
have a lower risk of having chronic pathologies when 
compared to nationals [37].
The risk factors for nationals showed results that are 
consistent with findings reported in the literature [3, 5]. 
Homeless and individuals with an HIV diagnosis had 
shorter total delays than individuals not homeless and 
without an HIV diagnosis, for nationals. These results are 
in line with the literature that suggests that these charac-
teristics are generally associated with shorter total delay, 
possibly because they are well-known risk factors for TB 
disease [3, 5]. The main differences between foreign-born 
and nationals are between patient and healthcare services 
delay [3, 31]. The risk factors identified as associated with 
delays in nationals, were not individually associated with 
delays in foreign-born individuals.
We also found that foreign-born individuals with 
comorbidities had higher healthcare services delay, 
although this association was only significant in the crude 
analysis (Additional file 1: Table S1), which is consistent 
with the literature [3]. National individuals with comor-
bidities had longer healthcare services delay, which might 
be due to similar symptoms presented by PTB patients 
and patients with other respiratory diseases, which may 
mislead health professionals [3]. In our study, having HIV 
infection seems to have divergent effects in these two 
populations, increasing the healthcare services delay in 
foreign-born and decreasing it for nationals [31]. How-
ever this results were only significant for nationals in the 
crude analysis (Additional file  1: Table  S1), thus further 
studies are necessary. This is possibly due to linguistic or 
cultural barriers that may delay the diagnosis, even after 
the first contact [31].
The absence of statistical significance for some vari-
ables in the regression analysis, especially concerning the 
delays in foreign-born, might be due to lack of power as 
a consequence of sample size in this population, since 
incarceration, homelessness, living in a community resi-
dence, and having respiratory comorbidities have lower 
frequencies in foreign-born individuals (n < 100). Also, 
we can speculate that this is due to the existence of 
other factors associated with PTB diagnosis for foreign-
born that are different from the commonly known fac-
tors described in the literature that also contribute to 
the delays and that may not be collected at the time of 
notification. Overall, this suggests the need for in-depth 
studies in the foreign-born population with PTB in order 
to identify specific risk factors that may contribute to 
the longer time until seeking healthcare services by this 
population.
A potential limitation of this study is recall bias, as the 
patient delay depends on a self-reported variable (symp-
toms onset). This is likely to have underestimated the 
patient delay, as patients might tend to place the begin-
ning of symptoms closer to the diagnosis. Even so, this 
is unlikely to have affected the associations identified as 
it is constant across notified cases. Collection of diagno-
sis and beginning of treatment dates can also pose limi-
tations, since we did not have access to information that 
allowed us to differentiate between the two dates. Exclu-
sion due to inconsistencies represented a very small num-
ber of individuals and is therefore unlikely to affect our 
results. In addition, individuals were deemed as foreign-
born based on the country of origin and we did not con-
sider how long they had lived in Portugal, which could 
impact the results, as some studies suggest [28, 36]. How-
ever, we performed an exploratory analysis with the time 
of stay in Portugal that showed foreign-born PTB cases 
had lived in Portugal for a median of 10 years. Addition-
ally, it is not known if they had PTB prior to entering the 
country.
This study also has several strengths. We used data 
from SVIG-TB, a well-established nationwide surveil-
lance system. To the best of our knowledge, this is the 
first study in Portugal that analysed diagnosis delay 
based on the origin country. Furthermore, we analysed 
patient and healthcare services delays separately, as fac-
tors affecting each of these dimensions could be different. 
Overall, these aspects afford us a better understanding 
of PTB delays amongst foreign-born, by showing that 
this population takes longer to have the final contact 
with healthcare services, but that from this point on, the 
beginning of treatment comes more quickly. These find-
ings enable oriented actions to tackle this difference, i.e., 
studying the factors that are preventing foreign-born 
from getting timely care. Additionally, our results sug-
gest that the factors contributing to the diagnostic delay 
in this population might not currently be obtained by the 
current notification system. There might, therefore, be 
alternative risk factors contributing to the delay in this 
population that need to be addressed.
Conclusions
This study identified different risk factors for patient 
and healthcare services delay amongst foreign-born 
persons and nationals, highlighting the importance 
to analyse each component of PTB diagnosis delay. 
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
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Foreign-born have greater patient delay compared to 
nationals with different risk factors, and thus tailored 
interventions should be implemented to guarantee 
timely access to healthcare services in this population. 
Additionally, the fact that few of the common risk fac-
tors associated with PTB were associated with delay in 
foreign-born could imply the existence of specific fac-
tors contributing to the delay in this population that 
need to be identified and addressed. Therefore, specific 
studies should be conducted to provide insightful infor-
mation related to the specific risk factors associated 
with diagnosis delay of PTB in foreign-born persons.
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